| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms MTX 1000, MTX1000 | 
| Target | 
| Action modulators | 
| Mechanism HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | China  | 03 Apr 2023 | |
| Lung Cancer | Preclinical | China  | 03 Apr 2023 | 






